http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109265565-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f68ddaa0ddd894016af217422d657c22 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f60c1dac6b67f1d019b06f0a08a3d3c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4abd47085dece1c038656f69168f14af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbf6f3130bdc150c54310182c6263aa4 |
| publicationDate | 2019-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109265565-A |
| titleOfInvention | Anti-CD79b chimeric antigen receptor carrying molecular switch and modified immune cell thereof and application thereof |
| abstract | The present invention relates to an anti-CD79b chimeric antigen receptor carrying a molecular switch and a modified immune cell thereof, and the same, wherein the anti-CD79b chimeric antigen receptor carrying a molecular switch comprises an anti-CD79b chimeric antigen receptor and is ligated The molecular switch on the anti-CD79b chimeric antigen receptor, the anti-CD79b chimeric antigen receptor comprises a signal peptide (Leader), an antigen binding domain domain capable of binding to the tumor surface antigen CD79b, and a hinge region (hinge) ), transmembrane domain, costimulatory signaling region, CD3ΞΆ signaling domain. The molecular switch-carrying anti-CD79b chimeric antigen receptor and immune cell of the invention have high structural stability and can be used for treating malignant tumors expressing CD79b surface antigen, and also preventing patients from being caused by off-target effects or cytokine release syndrome. The damage is higher and the safety is higher. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021099944-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113227145-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114891123-A |
| priorityDate | 2018-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 619.